

CERTIFICATE UNDER 37 CFR 1.10
'Express Mail' mailing label number: EL 544511765US
Date of Deposit: July 14, 2000
I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.
By: *Linda McCormick*
Name: Linda McCormick

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:
We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing Certificate under 37 CFR 1.10.
- ☒ Utility Patent Application: Spec. 16 pgs; 52 claims; Abstract 1 pgs.
The fee has been calculated as shown below in the 'Claims as Filed' table.
- ☒ 2 sheets of formal drawings
- ☒ Verified statement to establish small entity status
- ☒ A signed Combined Declaration and Power of Attorney
- ☒ Assignment of the invention to COLETICA, Recordation Form Cover Sheet
- ☒ A check in the amount of \$789.00 to cover the Filing Fee
- ☒ A check for \$40.00 to cover the Assignment Recording Fee.
- ☒ Other: Communication Regarding Priority Document(s); Communication Regarding Change of Correspondence Address
- ☒ Return postcard

CLAIMS AS FILED

Number of Claims Filed		In Excess of:		Number Extra		Rate		Fee
Basic Filing Fee								\$345.00
Total Claims								
52	-	20	=	32	x	9.00	=	\$288.00
Independent Claims								
7	-	3	=	4	x	39.00	=	\$156.00
MULTIPLE DEPENDENT CLAIM FEE								\$0.00
TOTAL FILING FEE								\$789.00

Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C.
P.O. Box 2903, Minneapolis, MN 55402-0903
(612) 332-5300

By: *John J. Gresens*
Name: John J. Gresens
Reg. No.: 33,112
Initials: JJG:jjw



Applicant or Patentee : Nabil ABDUL-MALAK & al, Docket No. : _____
Serial or Patent No. : _____ Examiner : _____
Filed or Issued : _____ Art Unit : _____
For : Processes for the preparation of novel collagen-based supports for tissue engineering and biomaterials obtained

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) and 1.27(c) - SMALL BUSINESS CONCERN)

I hereby declare that I am :

- () the owner of the small business concern identified below :
☒ an official of the small business concern empowered to act on behalf of the concern identified below :

NAME OF CONCERN : COLETICA
ADDRESS : 32 Rue Saint Jean de Dieu
69007 - LYON, France

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, DOES NOT EXCEED 500 PERSONS. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled Processes for the preparation of novel collagen-based supports for tissue engineering, and biomaterials obtained

by inventor(s) Nabil ABDUL MALAK, Valérie ANDRE, Alain HUC and described in :

- ☒ the specification filed herewith
() application serial No. _____, filed _____
() patent No. _____, issued _____

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e). *NOTE : SEPARATE VERIFIED STATEMENTS ARE REQUIRED FROM EACH NAMED PERSON, CONCERN OR ORGANIZATION HAVING RIGHTS TO THE INVENTION AVERRING TO THEIR STATUS AS SMALL ENTITIES (37 CFR 1.27).

NAME _____
ADDRESS _____
() INDIVIDUAL () SMALL BUSINESS CONCERN () NONPROFIT ORGANIZATION
() See attached sheet for additional person(s), concern(s) or organization(s).

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true : and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING : Pierre DEVICTOR TITLE : Président Directeur Général
ADDRESS : c/o COLETICA, 32 Rue St.Jean de Dieu, 69007 LYON, France

SIGNATURE Pierre DEVICTOR DATE : July 4, 2000

SUBJECT OF THE INVENTION

This invention relates to a composite product as a collagen support comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane consisting either of a collagen film prepared by trying a collagen gel, preferably in air or a gaseous fluid, or of a very highly compressed collagen sponge. This composite product may be used for the manufacture of artificial skin.

TECHNOLOGICAL BACKGROUND

For many years collagen has proved to be an irreplaceable substrate for the production of artificial tissues containing living cells.

The biomaterials obtained are increasingly used in the field of pharmaceuticals and they appear to have a very promising future for the preparation of injured connective tissues or for gene therapy by allowing the introduction and survival of modified cells in a living organism.

Furthermore, for "in vitro" tests, the cosmetic and dermopharmaceutical industries are increasingly using reconstructed skin, especially since animal tests are used less and less in these disciplines.

It is for this reason that several research teams throughout the world have been endeavoring to develop collagen-based supports for the production of living artificial tissues such as skin, cartilage, bone, tendon or reconstructed cornea, so these novel biomaterials have numerous fields of application.

It should be noted that the principal studies carried out in the field covered by the invention are attributable mainly to the following teams: Yannas I., Collombel C., Tinois E., Boyce S., Eisenberg H., Bell E., Kuroyanagi Y., Maruguchi T., Hanthamrongwit M., Auger F.A. and Osborne C.S.; cf. patent US 5,273,900, for example.

All these researchers use either collagen gels or collagen sponges, the latter being obtained by lyophilization.

The main difficulties to be overcome in the production of supports for the production of living artificial tissues are as follows: good mechanical strength, low sensitivity to temperatures around 37°C, biological properties favorable to cell development and metabolism, low susceptibility to enzymatic degradation and, finally, for certain applications and particularly reconstructed skin, preferably the presence of a bilayer structure in which one of the layers is as compact as possible

and the other is porous.

The researches carried out hitherto have not provided collagen supports which satisfactorily comply with all the constraints listed above.

PURPOSES OF THE INVENTION

The object of the present invention is to solve these problems which have remained shelved from both the technical and industrial points of view.

The present invention makes it possible to solve all these technical problems in a particularly simple, inexpensive manner applicable to the industrial scale, particularly in cosmetics, dermopharmaceutics or pharmaceutics.

SUMMARY OF THE INVENTION

According to a first feature, the present invention provides a novel composite product forming a collagen support comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane consisting either of a collagen film prepared by drying a collagen gel, preferably in air or a gaseous fluid, or of a very highly compressed collagen sponge.

According to yet another advantageous characteristic of the composite product of the invention, the collagen sponge is compressed at a pressure of at least about 50 bar, equivalent to about $50 \cdot 10^5$ Pascals (Pa), and preferably of between 50 bar ($50 \cdot 10^5$ Pa) and 200 bar ($200 \cdot 10^5$ Pa), this compression optionally taking place at a temperature of between 20 and 80°C and preferably of between 40°C and 60°C.

According to one advantageous characteristic of this composite product, the collagen product is selected from collagen and a mixture of collagen with a polysaccharide, particularly a glycosaminoglycan, chitosan or a derivative thereof, cellulose or a derivative thereof, dextran or a derivative thereof, an alginate or a derivative thereof, or a carrageenan.

According to another advantageous characteristic of this composite product, at least one of the two layers of the latter, i.e. the porous layer and the essentially compact membrane, comprises normal, genetically modified or malignant living cells originating particularly from young or elderly subjects.

In one advantageous variant, the living cells are selected from the group consisting of fibroblasts, keratinocytes, melanocytes, Langerhans' cells originating

from the blood, endothelial cells originating from the blood, blood cells, particularly macrophages or lymphocytes, adipocytes, sebocytes, chondrocytes, osteocytes, osteoblasts and Merkel's cells originating from the blood, said cells being normal, genetically modified or malignant.

According to yet another advantageous characteristic, the composite product contains normal, genetically modified or malignant fibroblasts in the porous layer and normal, genetically modified or malignant living cells on the surface of the compact membrane, said cells being selected particularly from keratinocytes, melanocytes, Merkel's cells originating from the blood, Langerhans' cells originating from the blood, sebocytes, cells originating from the blood, and nerve cells.

In yet another advantageous embodiment of the invention, it can be of particular value to prepare either "young" reconstructed skin using cells taken substantially exclusively from young subjects, or "aged" reconstructed skin obtained from cells taken substantially exclusively from elderly subjects. These models will make it possible to improve our knowledge of the skin ageing process and study the influence of active agents on this process.

In yet another advantageous embodiment of the invention, the essentially compact membrane is prepared prior to combination with the porous layer, preferably comprising a collagen sponge, in particular by preparing the membrane and depositing it on a collagen gel before the whole is frozen and lyophilized to give said composite product.

In yet another embodiment of the composite product according to the invention, the collagen sponge and/or the collagen film and/or the collagen membrane of said product comprise collagen of mammalian origin, particularly of bovine origin.

In yet another advantageous embodiment of the composite product according to the invention, at least one of the two layers of said product is produced from a collagen gel containing a mixture of soluble collagen and insoluble collagen, for example in the form of fibers.

In the case of the composite product according to the invention, the collagen can be type I and/or type III collagen.

According to a second feature, the present invention also covers a process for the manufacture of a composite product comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane,

09646526-07400

wherein:

a) first of all the essentially compact collagen membrane is prepared either by drying a first collagen gel, preferably in air or with the aid of a gaseous fluid, or by compressing a collagen sponge obtained by the freezing-lyophilization of a collagen gel;

b) a second collagen gel is prepared separately;

c) either the essentially compact membrane is deposited on the second collagen gel, or the second collagen gel is poured onto the essentially compact membrane; and finally

d) the whole is frozen-lyophilized to give said composite product.

In one advantageous variant of this process, the collagen sponge used to prepare the compact membrane is compressed at a pressure of at least 50 bar (about $50 \cdot 10^5$ Pa) and preferably of between 50 bar ($50 \cdot 10^5$ Pa) and 200 bar ($200 \cdot 10^5$ Pa).

The compression step advantageously takes place at a temperature of between 20 and 80°C and preferably of between 40°C and 60°C.

In another advantageous embodiment of this process, the collagen sponge and/or the collagen film and/or the collagen membrane are prepared using either collagen or a mixture of collagen with a polysaccharide, particularly a glycosaminoglycan, chitosan or a derivative thereof, cellulose or a derivative thereof, dextran or a derivative thereof, an alginate or a derivative thereof, or a carrageenan.

In another variant of the process, at least one of the two layers, or both layers, are crosslinked.

In one advantageous variant, the above-mentioned crosslinking is a physical crosslinking, particularly a thermal dehydration under vacuum, or TDH, or a chemical crosslinking, particularly with diphenylphosphorylazide, or DPPA, with an aldehyde such as glutaraldehyde, with carbodiimide or with succinimide.

In another advantageous variant of this process, a compound which favors cell development, particularly a growth factor and especially a cytokine or a chemokine, is added during manufacture.

In another advantageous embodiment of the process according to the invention, provision is made for a step for the introduction of normal, genetically modified or malignant living cells into at least one of the two layers.

In one advantageous variant, said living cells are selected from the group consisting of fibroblasts, keratinocytes, melanocytes, Langerhans' cells originating

from the blood, endothelial cells originating from the blood, blood cells, particularly macrophages or lymphocytes, chondrocytes, osteocytes, particularly osteoblasts, Merkel's cells originating from the blood, sebocytes, adipocytes and nerve cells.

In one particularly advantageous embodiment of the invention, the process comprises introducing fibroblasts into the porous layer.

In a more preferred embodiment of the invention, the process comprises depositing living cells on the surface of the compact membrane, said cells being selected particularly from keratinocytes, melanocytes, Merkel's cells originating from the blood, Langerhans' cells originating from the blood, sebocytes, cells originating from the blood, and nerve cells.

In one variant of the process of the invention, the living cells are provided either by the sequential culture or by the concomitant culture of the different types of cells, these cells originating from culture or biopsy.

According to a third feature, the present invention also covers the use of the composite product forming a collagen support as defined above, or as obtained by the process defined above, or as resulting from the following description relating especially to the Examples, for which every characteristic which appears to be novel compared with any state of the art is claimed as such in its function and in its generality, for the manufacture of artificial skin intended especially for performing in vitro tests on the efficacy of a potentially active substance or for reconstructing damaged areas of skin in vivo.

According to one advantageous characteristic, the artificial skin can be obtained either substantially exclusively from young cells or substantially exclusively from aged cells, in particular for studying the tissue ageing process, especially the skin ageing process, and optionally for testing the efficacy of active principles on this process.

The invention also covers any artificial skin comprising living cells obtained either substantially exclusively from young cells or substantially exclusively from aged cells, in particular for studying the tissue ageing process, especially the skin ageing process, and optionally for testing the efficacy of active principles on this process. Specific embodiments of this artificial skins comprise the composite product according to the instant invention as a best embodiment.

Thus it is seen that the invention provides a solution to the above-mentioned technical problems.

09646526 074400

To obtain the strongest collagen materials, the inventors carried out more particularly the process described in patent US 5 333 092 granted on 19 July 1994. This technique affords a mixture of soluble and insoluble type I and type III native collagens which are very strong from the mechanical point of view and very resistant to enzymatic digestion. These last two characteristics may optionally be improved by any crosslinking technique or by the addition of substances which interact strongly with collagen and do not exhibit toxicity towards the cells. Furthermore, this collagen production process makes it possible virtually to eliminate the risk of biological contamination due to bacteria, viruses or prions.

For the case of supports intended for obtaining reconstructed skin, the inventors came to the idea of preparing bilayer materials by producing firstly the more compact layer and then the porous sponge. This methodology has the advantage of resulting in a much more compact surface layer than all those described hitherto. In particular, sponges compacted by high compression, or films, can therefore be fixed to porous matrices.

The use of the supports described above for tissue engineering applications involves the inoculation of living or genetically modified cells, it being possible for the cells to develop either inside the collagen support or on its surface.

The reconstructed living tissues obtained in this way can be used in numerous cosmetic, dermopharmaceutical or pharmaceutical applications as:

- . "in vitro" models for simulating the effects of ingredients on cell metabolisms for the purpose of evaluating the efficacy and toxicity of raw materials or more complex formulations;
- . reconstructed tissues capable of overcoming the deficiencies of damaged tissues: skin, cartilage, bone, tendon, cornea; or
- . living implants containing modified cells capable of overcoming certain deficiencies of the organism, particularly in the field of gene therapy.

BRIEF DESCRIPTION OF THE EXAMPLES AND OF THE DRAWINGS

Other objects, characteristics and advantages of the invention will become clearly apparent from the following explanatory description referring to various Examples of the invention, which are given simply by way of illustration and cannot therefore in any way limit the scope of the invention. As indicated previously, any characteristic in the Examples which appears to be novel compared

with any state of the art is claimed in its function and in its generality, independently of the context of the Example. Moreover, Examples 6 to 13 constitute currently preferred embodiments of the composite products according to the invention which form a collagen support. Example 14 refers to comparative tests demonstrating the value of the composite products according to the invention as collagen supports for the manufacture of artificial skin intended especially for performing in vitro tests on the efficacy of a potentially active substance or for reconstructing damaged areas of skin in vivo.

Example 15 shows a test for the use of a composite product according to the invention which constitutes an artificial skin prepared from cells of young donors, compared with reconstructed skin obtained from cells of elderly donors, within the framework of a procedure for testing the efficacy of an active principle in order to study the skin ageing process, especially by quantification of the laminins produced.

In the attached Figures:

- Figure 1 shows a sectional view, after marking by conventional histological staining, of a composite product according to the present invention which has been produced from a porous lower layer of bovine collagen covered on the top side with an essentially compact upper collagen membrane consisting of a collagen film prepared by drying a collagen gel in air under the conditions of Example 6;

- Figure 2 shows a similar section obtained with a simple porous matrix which has been prepared with the same bovine collagen gel, except that it has not been covered, i.e. under the conditions of Example 1, showing the presence of deep inclusions of keratinocytes not limited to the surface;

- Figure 3 shows the quantity of laminins present in the reconstructed skin incubation media, respectively for young reconstructed skin obtained from cells taken from donors of 25 to 35 years of age, and for mature or aged reconstructed skin obtained from cells taken from donors of more than 55 years of age, in order to show the influence of the donor's age, the results being expressed in the form of "bars" and the quantity of laminins produced being expressed on the ordinate as a percentage of the control (YRS = young reconstructed skin);

- Figure 4 shows the inductive effect of a fermented malt extract commercially available under the trade mark BASALINE®, COLETICA, France, on the production of laminins in mature reconstructed skin, the quantity of laminins

produced again being expressed as a percentage of the control; and

- Figure 5 shows the compensating effect of the same fermented malt extract, or BASALINE®, the quantity of laminins produced being expressed on the ordinate as a percentage of the control.

DETAILED DESCRIPTION OF THE INVENTION

EXAMPLE 1 OF THE INVENTION

Preparation of a porous matrix of native collagen by the technique of patent US no. 5331092

A - Preparation of the native collagen

A gel is prepared from calf skins which have previously been washed (2 hours) and then depilated with a lime/sulfide mixture (lime: 3.5%, sodium sulfide: 2.5%) at a rate of 400 g of skin (solids content: about 30%) to 250 ml of water. This bath lasts for 30 minutes with rotation at 4 rpm.

The total depilation time is 36 hours.

The skins are then unlimed in a bath containing ammonium chloride (3%) and sodium metabisulfite (0.5%) at a rate of 400 g of skin to 50 ml of bath.

The total duration of this bath is 2 hours thirty minutes.

The salts are removed by two successive washes with water (15 minutes per wash) at a rate of 200 ml of water to 100 g of tissue.

The skins are subsequently ground and then washed by agitation for 1 hour with phosphate buffer of pH 7.8 (0.78 g/l of potassium dihydrogenphosphate and 21.7 g/l of disodium monohydrogenphosphate) at a rate of 5 l buffer/kg ground material. The phosphate is then removed by two successive washes with softened water and then by continuous centrifugation at 4000 rpm (Rousselet centrifuge) at a rate of 5 l of water per kg of ground material.

The ground material is then acidified with 10% acetic acid solution, the amount of acetic acid being 5% based on the collagen; the final molarity is about 0.08 M.

The ground material is then malaxated for one hour to give a paste.

The gel is obtained by continuously passing the paste through a UTL T/-6 ultrasonic treatment apparatus. This gel has a concentration of between 0.7 and 2% of collagen, the proportion of acid-soluble collagen varying from

09646555 "074400

10 to 20% based on the insoluble collagen.

B - Preparation of the porous matrix with the collagen gel obtained as indicated above

20 g/cm² of collagen gel (solids content = 0.75%) are placed in a lyophilization tray and lyophilized by freezing at -30°C and then heating at +32°C. The total lyophilization time is 16 hours under a pressure of 400 microbar.

The lyophilizate is crosslinked by a physical method (TDH), the lyophilizate being placed for 10 hours in an oven at 110°C and 400 microbar of pressure.

EXAMPLE 2 OF THE INVENTION

Preparation of a porous matrix crosslinked with diphenylphosphorylazide (DPPA) by the technique described in European patent no. 466 829 of 24 July 1996

The collagen lyophilizate is incubated for 24 h in a solution containing 5 to 250 µl DPPA/g collagen in 100 ml of dimethylformamide (DMF). The collagen is then rinsed in 100 ml of DMF to remove the DPPA. The DMF is then removed by rinsing in 100 ml of a borate buffer solution of pH 8.9 (0.04 M sodium tetraborate, 0.04 M boric acid).

The collagen is finally incubated overnight in the same borate buffer, the borate buffer then being removed by continuous rinsing with softened water for 6 h.

EXAMPLE 3 OF THE INVENTION

Preparation of a porous matrix crosslinked with carbodiimide and N-hydroxysuccinimide

The collagen is crosslinked with EDC (ethyldimethylaminopropylcarbodiimide) at a concentration of 0.23 to 0.69 g/g collagen and with NHS (N-hydroxysuccinimide) at a concentration of 0 to 0.42 g/g collagen.

After rinsing with softened water, the collagen is lyophilized again.

EXAMPLE 4 OF THE INVENTION

Preparation of a porous matrix crosslinked with glutaraldehyde

The collagen is crosslinked for 24 to 96 h in a solution containing 0.6 to 1% of GTA at 20°C.

00416526 004400

After rinsing with softened water, the collagen is lyophilized again.

EXAMPLE 5 OF THE INVENTION

Porous matrix prepared with the native collagen of Example 1 in association with chitosan and a glycosaminoglycan as described in European patent no. 296078 of 29 May 1991

A solution of 2.5 g of chitosan in 356 ml of water and 1.9 ml of acetic acid, and then a solution containing 1 g of chondroitin 4-sulfate in 400 ml of softened water, are added to 600 g of 1.5% collagen gel. The mixture, which has a pH of about 4.0, is subsequently agitated and then lyophilized. The sponge obtained is crosslinked by TDH.

EXAMPLE 6 OF THE INVENTION

Porous matrix described in Example 1, covered with a collagen film

A - Preparation of the film

Collagen gel with a solids content of between 0.3 and 0.8% is dried in an oven at 30°C or under a hood at a rate of 0.5 g gel/cm² tray.

10 to 40% of glycerol can be added to the collagen gel.

The collagen dried under these conditions forms a transparent film.

B - Association of the film with the porous matrix described above

0.5 g/cm² of collagen gel of example 1 with a solids content of 0.75% is placed in a lyophilization tray, the collagen film is then deposited on this gel and the whole is lyophilized.

The lyophilizate obtained is crosslinked by TDH.

EXAMPLE 7 OF THE INVENTION

Porous matrix prepared with an acid-soluble collagen gel and covered with a collagen film

The process is that indicated in Example 6, the only difference being in the nature of the gel poured onto the film, which consists of acid-soluble collagen prepared by a technique well known to those skilled in the art.

EXAMPLE 8 OF THE INVENTION

Porous matrix prepared with an atelocollagen gel and covered with a collagen film

The process is that indicated in Example 6, the only difference being in the

nature of the gel poured onto the film, which consists of atelocollagen, i.e. telopeptide-free collagen prepared by a technique well known to those skilled in the art.

EXAMPLE 9 OF THE INVENTION

Porous matrix consisting of collagen associated with chitosan and a glycosaminoglycan and covered with a collagen film

The process is that indicated in Example 6 except that in this case the gel poured onto the collagen film consists of collagen, chitosan and a glycosaminoglycan. The preparation of this gel is described in Example 5.

EXAMPLE 10 OF THE INVENTION

All the porous matrices described above, covered with a collagen film, can be crosslinked by the techniques described in Examples 2, 3 and 4.

EXAMPLE 11 OF THE INVENTION

Porous matrix of collagen only, described in Example 1, covered with a compressed collagen sponge

A - Preparation of the compressed sponge

Collagen gel prepared as in Example 1, with a solids content of between 0.3 and 1.5%, is lyophilized to give a sponge weighing between 0.5 and 2 g/cm².

The lyophilizate is compressed for 5 to 60 seconds at a temperature of between 20 and 60°C and a pressure of between 50 and 200 bar (50 to 200.10⁵ Pa).

B - Association of the compressed sponge with the porous matrix

The collagen gel described in Example 1 is deposited in a lyophilization tray at a rate of 0.5 g per cm². The compressed sponge is then deposited on this gel and the whole is lyophilized to give a porous collagen sponge covered with a compressed collagen sponge. The whole is crosslinked by TDH as described in Example 1.

EXAMPLE 12 OF THE INVENTION

Porous matrix consisting of collagen, chitosan and glycosaminoglycan, as described in Example 5, covered with compressed sponge

09616526 034400

The collagen, chitosan and glycosaminoglycan gel prepared by the process of Example 5 is deposited in a lyophilization tray at a rate of 0.5 g per cm², the compressed sponge is then deposited on this gel and the whole is lyophilized. The lyophilizate is then crosslinked by TDH as described in Example 1.

EXAMPLE 13 OF THE INVENTION

All the porous matrices described above, covered with a compressed collagen sponge, can be crosslinked by the techniques described in Examples 2, 3 and 4.

EXAMPLE 14 OF THE INVENTION

Reconstructed skin prepared either with the aid of the DPPA-crosslinked porous matrix described in Example 2, or with the aid of the DPPA-crosslinked porous matrix of Example 2 covered with a compressed collagen sponge, the whole being crosslinked with DPPA, according to Example 13, in order to allow a comparison to be made between a composite product comprising a porous collagen layer covered with an essentially compact membrane according to the invention and a product comprising a porous collagen layer only, with no covering

Preparation of reconstructed skin

a) Culture of normal human fibroblasts

Normal human fibroblasts taken arbitrarily from elderly or young subjects are used; they are recovered and developed in a manner conventional to those skilled in the art for recovery between the sixth and tenth passages.

Inoculation is carried out at a rate of 250,000 cells per cm² of porous matrix, the latter being either the comparison product comprising only the DPPA-crosslinked porous matrix of Example 2, or the composite product according to the invention comprising the DPPA-crosslinked porous matrix of Example 2 covered with a compressed collagen sponge, the whole being crosslinked with DPPA, according to Example 13.

The culture medium is composed of DMEM/HAM F12 50/50 (v/v) supplemented with 10% by weight of fetal calf serum, 100 IU/ml of penicillin, 25 µg/ml of gentamycin, 1 µg/ml of amphotericin B and 50 µg/ml of vitamin C.

Culture is carried out for three weeks, the medium being changed three times a week.

b) Culture of normal human keratinocytes

Normal human keratinocytes obtained arbitrarily from young or elderly subjects are then cultured; they are recovered and cultivated by the culture techniques well known to those skilled in the art for recovery between the first and third passages.

Inoculation is carried out at a rate of 250,000 cells per cm^2 of surface, which is either the surface of the DPPA-crosslinked porous matrix of Example 2, or the surface of the composite product according to the invention comprising the DPPA-crosslinked porous matrix of Example 2 covered with a compressed collagen sponge, the whole being crosslinked with DPPA, according to Example 13, in which case the keratinocytes are inoculated onto the surface of the essentially compact collagen membrane.

The culture of these products, comprising an inoculation of both fibroblasts and keratinocytes, takes place in a Green's medium composed of:

DMEM supplemented with:

30% of HAM F12,

10% of fetal calf serum,

100 IU/ml of penicillin,

100 $\mu\text{g/ml}$ of streptomycin,

1 $\mu\text{g/ml}$ of amphotericin B,

2 $\mu\text{mol/ml}$ of L-glutamine,

10 ng/ml of EGF (Epidermal Growth Factor),

0.12 IU/ml of insulin commercially available under the trade mark UMULINE[®],

400 ng/ml of hydrocortisone,

10^{-12} mol/ml of cholera toxin,

5 $\mu\text{g/ml}$ of transferrin,

$2 \cdot 10^{-9}$ M triiodothyronine,

$1.8 \cdot 10^{-7}$ mol/ml of adenine,

50 $\mu\text{g/ml}$ of vitamin C.

This culture is carried out for one week, the media being changed every day.

c) Culture of the composite product according to the invention and the comparative non-covered porous layer

After the culture of step b) has been carried out for one week with the

media being changed every day, the surface layer containing the keratinocytes is caused to emerge at the air-liquid interface, while the layer containing the fibroblasts remains immersed, and culture is then carried out for three weeks in an emersion medium composed of:

DMEM supplemented with:

10% of fetal calf serum,

100 IU/ml of penicillin,

100 µg/ml of streptomycin,

1 µg/ml of amphotericin B,

2 µmol/ml of L-glutamine,

10 ng/ml of EGF,

0.12 IU/ml of insulin of trade mark UMULINE[®],

400 ng/ml of hydrocortisone,

50 µg/ml of vitamin C.

The total culture time of 7 weeks resulting from steps a) to c) gives a reconstructed skin composed of a reconstructed dermis, the fibroblasts having colonized the three-dimensional collagen matrix, said dermis being covered with a multilayer epidermis.

The dermo-epidermal interface shows the presence of a basal membrane in which it is possible to identify the presence of laminin-1, laminin-5, type IV collagen and type VII collagen by immunolabeling.

Thus, after three weeks of preparation of the dermis equivalent, covering of the porous matrices with an essentially compact layer to give a composite product according to the invention affords a greater quantity of fibroblasts on the surface of the collagen matrices before epidermization.

In the case of a porous matrix only, i.e. with no covering, if the surface layer of fibroblasts is not completely contiguous, keratinocytes can infiltrate the underlying dermis equivalent and form islets of keratinocytes, which are totally abnormal features.

Thus it is seen that the invention, which uses more compact layers than those previously available for use in the prior art, provides better security against the penetration of keratinocytes.

It is pointed out that the abbreviation DMEM in the description denotes Dulbecco Modified Eagle's Medium.

EXAMPLE 15 OF THE INVENTION

Study comparing skin reconstructed from cells of young donors and skin reconstructed from cells of elderly donors with the composite products according to the present invention in order to measure the efficacy of active principles on the production of laminins

The procedure in this Example is essentially as described in Example 14 as regards the cultures, using the same composite product according to the present invention comprising a DPPA-crosslinked porous collagen layer or matrix described in Example 2, covered with a compressed collagen sponge, the whole being crosslinked with DPPA, according to Example 13. The procedure is as follows:

1) Preparation of the reconstructed skin

Young reconstructed skin was prepared by the procedure described in Example 14 except that the fibroblasts and keratinocytes originated respectively from young donors, i.e. those of between 25 and 35 years of age. Also, aged or mature reconstructed skin was obtained by using fibroblasts or keratinocytes originating from elderly donors of more than 55 years of age.

a) Materials and method

As indicated in Example 14, step a, porous matrices of the composite product of the invention were first inoculated with normal human dermal fibroblasts originating either from pools of young cells or from pools of mature or aged cells, and culture is carried out for 21 days under the conditions described in Example 14, step a.

b) After the above-mentioned 21 days of culture, epidermal layers prepared separately from keratinocytes originating either from pools of young cells or from pools of mature cells are inoculated onto the surface of the essentially compact collagen membrane of the composite product.

Culture is carried out for 14 days under the conditions described in Example 14b.

2) Quantification of the laminins

After the 14 days of culture of the fibroblast-keratinocyte composite, the laminins contained in the incubation media of the resulting young or mature reconstructed skin are quantified with the aid of a commercially available ELISA kit (Takara, Japan).

These results are reported in Figure 3.

09646526-071400

Figure 3 shows that the mature reconstructed skin contains about half as much laminins as the young reconstructed skin (YRS) used as 100% control.

3) Measurement of the inductive effect of an active principle, such as a fermented malt extract marketed by COLETICA under the trade mark BASALINE®, on the production of laminins in young and mature reconstructed skin

In this comparative test, the procedure is as described above except in regard to the 14 days of culture with keratinocytes; the young or mature reconstituted skin is maintained in culture for 14 days either in the absence (control) or in the presence of 0.5% by weight of fermented malt extracts commercially available under the trade mark BASALINE®, COLETICA, France.

At the end of the incubation period, as in the above Example, the laminins contained in the incubation media were quantified by ELISA.

The results are reported in Figure 4.

The 100% control consists of the proportion of laminins in Aged Reconstructed Skin, or ARS.

Figure 4 shows that the active principle extracted from fermented malt, or BASALINE®, was capable of stimulating laminin production in mature reconstructed skin. Under the same conditions, the active principle extracted from fermented malt, or BASALINE®, does not significantly modify laminin production in young reconstructed skin, as indicated in Figure 5.

Thus it is seen that the active principle extracted from fermented malt, or BASALINE®, increases laminin production in mature reconstructed skin by 65%.

By the same token, this active principle does not affect the physiological processes involved in the regulation of laminin production in young reconstructed skin.

These experiments made it possible to evaluate the magnitude of the compensating effect of the fermented malt extract, or BASALINE®, defined as the capacity of this active principle to reduce the relative difference observed between laminin production in young reconstituted skin and that in mature reconstituted skin.

Figure 5 shows that the difference between laminin production in young reconstituted skin and that in mature reconstituted skin can be reduced by 65% when the active principle is used at 0.5%.

WHAT IS CLAIMED IS:

1. A composite product forming a collagen support comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane selected from the group consisting of a collagen film prepared by drying a collagen gel and from a compressed collagen sponge.
2. The product according to claim 1 wherein said collagen gel is dried in a fluid selected from air and a gaseous fluid.
3. The product of claim 1, wherein the collagen of at least one of the porous layer and of the essentially compact membrane is selected from collagen and a mixture of collagen with a substance selected from a the group consisting of a polysaccharide, , a cellulose, dextran, an alginate and a carrageenan.
4. The product of claim 3 wherein said polysaccharide is selected from glycosaminoglycan and chitosan.
5. The product of claim 1 wherein at least one of the porous layer and of the essentially compact membrane, comprises living cells selected from normal living cells, genetically modified living cells and malignant living cells.
6. The product of claim 5, wherein said living cells are originating substantially exclusively from young subjects.
7. The product of claim 5, wherein said living cells are originating substantially exclusively from elderly subjects.
8. The product of claim 5, wherein the living cells are selected from the group consisting of fibroblasts, keratinocytes, melanocytes, Langerhans' cells originating from the blood, endothelial cells originating from the blood, blood cells, particularly macrophages or lymphocytes, adipocytes, sebocytes, chondrocytes, osteocytes, osteoblasts and Merkel's cells originating from the blood, said cells being normal, genetically modified or malignant.
9. A composite product forming a collagen support comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane selected from a collagen film prepared by drying a collagen gel and from a compressed collagen sponge, said porous layer comprising living fibroblasts and said essentially compact membrane comprising on the surface thereof living cells selected from the group consisting of keratinocytes, melanocytes, Merkel's cells originating from the blood, Langerhans' cells originating from the blood, sebocytes, cells originating from the blood, and nerve

00616526-071400

cells.

10. The product of claim 1, wherein the collagen sponge is compressed at a pressure of at least about 50 bar, equivalent to about $50 \cdot 10^5$ Pa, this compression optionally taking place at a temperature ranging between 20 and 80°C.

11. The product of claim 10, wherein the pressure ranges between 50 bar ($50 \cdot 10^5$ Pa) and 200 bar ($200 \cdot 10^5$ Pa), this compression optionally taking place at a temperature ranging between 40°C and 60°C.

12. The product of claim 1, wherein the essentially compact membrane is prepared prior to combination with the porous layer.

13. The product of claim 12, wherein after having prepared the essentially compact membrane, the collagen gel is deposited on at least one surface of the essentially compact membrane and the combination of the collagen gel with the essentially compact membrane is frozen and lyophilised to give said composite product.

14. The product of claim 1, wherein the collagen comprises mammalian collagen.

15. The product of claim 1, wherein the collagen comprises bovine collagen.

16. The product of claim 1, wherein at least one of the two layers is produced from a collagen gel containing a mixture of soluble collagen and insoluble collagen.

17. The product of claim 16 wherein said insoluble collagen is comprising collagen fibers.

18. The product of claim 1 wherein the collagen is selected from the group consisting of type I collagen and type III collagen.

19. The product of claim 1, wherein at least one of the two layers is produced from a collagen gel containing a mixture of soluble collagen and insoluble collagen, wherein the collagen is selected from the group consisting of type I collagen and type III collagen.

20. A process for the manufacture of a composite product comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane, wherein:

a) the essentially compact collagen membrane is prepared either by drying a first collagen gel, or by compressing a collagen sponge obtained by the freezing-lyophilization of a collagen gel;

b) a second collagen gel is prepared separately;

c) either the essentially compact membrane is deposited on the second collagen gel, or the second collagen gel is poured onto the essentially compact membrane; and finally

d) the whole is frozen-lyophilized to give said composite product.

21. The process according to claim 20 wherein the collagen sponge used to prepare the essentially compact membrane is compressed at a pressure of at least 50 bar ($50 \cdot 10^5$ Pa)
22. The process of claim 20, wherein the collagen sponge is compressed at a pressure ranging between 50 bar ($50 \cdot 10^5$ Pa) and 200 bar ($200 \cdot 10^5$ Pa).
23. The process of claim 20 wherein the compression step takes place at a temperature of between 20 and 80°C.
24. The process of claim 20, wherein the collagen is selected from collagen and a mixture of collagen with a substance selected from the group consisting of a polysaccharide, cellulose, dextran, an alginate and a carrageenan.
25. The process of claim 24, wherein the polysaccharide is selected from a glycosaminoglycan and chitosan.
26. The process of claim 20, wherein said collagen comprises or is essentially consisting of mammalian collagen.
27. The process of claim 20, wherein said collagen comprises or is essentially consisting of bovine collagen.
28. The process of claim 20, wherein at least one of the two layers, or both layers, are crosslinked.
29. The process of claim 28, wherein the crosslinking is selected from the group consisting of a physical crosslinking, a chemical crosslinking, and a combination thereof.
30. The process of claim 29, wherein said physical crosslinking is a thermal dehydration under vacuum.
31. The process of claim 29, wherein said chemical crosslinking is selected from the group consisting of a crosslinking with diphenylphosphorylazide, a crosslinking with an aldehyde, a crosslinking with glutaraldehyde, a crosslinking with a carbodiimide, a crosslinking with a succinimide and combinations thereof.
32. The process of claim 20, wherein a compound which favors cell development is added during manufacture.
33. The process of claim 32, wherein said compound which favors cell development is selected from the group consisting of a growth factor, cytokine and

a chemokine

34. The process of claim 20, wherein living cells are introduced into at least one of the two layers.

35. The process of claim 34, wherein said living cells are selected from the group consisting of normal living cells, genetically modified living cells and malignant living cells.

36. The process of claim 34, wherein said living cells are originating substantially exclusively from young subjects.

37. The process of claim 34, wherein said living cells are originating substantially exclusively from elderly subjects.

38. The process of claim 34, wherein said living cells are selected from the group consisting of fibroblasts, keratinocytes, melanocytes, Langerhans' cells originating from the blood, endothelial cells originating from the blood, blood cells, particularly macrophages or lymphocytes, chondrocytes, osteocytes, particularly osteoblasts, Merkel's cells originating from the blood, sebocytes, adipocytes and nerve cells.

39. The process of claim 20, wherein living fibroblasts are introduced into the porous layer.

40. The process of claim 20, wherein living cells are deposited on the surface of the compact membrane, said cells being selected from the group consisting of keratinocytes, melanocytes, Merkel's cells originating from the blood, Langerhans' cells originating from the blood, sebocytes, cells originating from the blood, and nerve cells.

41. The process of claim 34, wherein the living cells are provided either by the sequential culture or by the concomitant culture of the different types of cells, these cells originating from culture or biopsy.

42. An artificial skin comprising a composite product as defined in claim 1.

43. An artificial skin comprising a composite product as defined in claim 9.

44. The artificial skin of claim 42, comprising living cells obtained substantially exclusively from young cells from young subjects.

45. The artificial skin of claim 42, wherein said artificial skin comprising living cells obtained substantially exclusively from aged cells from elderly subjects.

46. An artificial skin comprising living cells essentially prepared from substantially exclusively young cells originated from young subjects.

47. An artificial skin comprising living cells essentially prepared from

substantially exclusively aged cells originated from elderly subjects.

48. A method of in vitro testing of the efficacy of a potential active substance comprising using an artificial skin comprising living cells prepared substantially exclusively from young cells taken from young subjects.

49. A method of in vitro testing of the efficacy of a potential active substance comprising using an artificial skin comprising living cells prepared substantially exclusively from aged cells taken from elderly subjects.

50. A method of reconstructing damaged areas of skin in vivo comprising performing said reconstruction with an artificial skin prepared essentially from a composite product as defined in claim 1.

51. A method of reconstructing damaged areas of skin in vivo comprising performing said reconstruction with an artificial skin prepared essentially from a composite product as defined in claim 9.

52. The method of claim 51, wherein at least one of the two layers is produced from a collagen gel containing a mixture of soluble collagen and insoluble collagen, the collagen being selected from the group consisting of type I collagen and Type III collagen.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

entitled: Processes for the preparation of novel collagen-based supports for tissue engineering, and biomaterials obtained

in the names of: Nabil ABDUL MALAK
Valérie ANDRE
Alain HUC

Assignee: COLETICA

ABSTRACT OF THE DISCLOSURE

A composite product is disclosed as a collagen support comprising at least one porous collagen layer covered on at least one side with an essentially compact collagen membrane consisting either of a collagen film prepared by drying a collagen gel, preferably in air or a gaseous fluid, or of a very highly compressed collagen sponge. At least one of the two layers, i.e. the porous layer and the essentially compact membrane, may comprise normal, genetically modified or malignant living cells originating particularly from young or elderly subjects. This composite product is used as a collagen support for the manufacture of artificial skin intended especially for performing in vitro tests on the efficacy of potentially active substances or for reconstructing damaged areas of skin in vivo.

Figure 1

09616526-071400

COVERED BOVINE MATRIX



FIG.1
INVENTION

NON-COVERED BOVINE MATRIX




FIG.2
PRIOR ART

004729 9259T960




FIG.3




FIG.4




FIG.5

United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

As a below named inventor I hereby declare that: my residence, post office address and citizenship are as stated below next to my name; that

I verily believe I am the original, first and sole inventor (if only one name is listed below) or a joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Processes for the preparation of novel collagen-based supports for tissue engineering, and biomaterials obtained

The specification of which

a. ☒ is attached hereto

b. ☐ was filed on _____ as application serial no. _____ and was amended on _____ (if applicable) (in the case of a PCT-filed application) described and claimed in international no. _____ filed _____ and as amended on _____ (if any), which I have reviewed and for which I solicit a United States patent.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56 (see page 3 attached hereto).

I hereby claim foreign priority benefits under Title 35, United States Code, § 119/365 of any foreign application(s) for patent of inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on the basis of which priority is claimed:

a. ☐ no such applications have been filed.

b. ☐ such applications have been filed as follows:

FOREIGN APPLICATION(S), IF ANY, CLAIMING PRIORITY UNDER 35 USC § 119

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)
France	00 06743	26/05/2000	

ALL FOREIGN APPLICATION(S), IF ANY, FILED BEFORE THE PRIORITY APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING (day, month, year)	DATE OF ISSUE (day, month, year)

I hereby claim the benefit under Title 35, United States Code, § 120/365 of any United States and PCT international application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. APPLICATION NUMBER	DATE OF FILING (day, month, year)	STATUS (patented, pending, abandoned)

I hereby appoint the following attorney(s) and/or patent agent(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected herewith:

093

Adriano, Saran B.	Reg. No. 34,470	Gabilan, Mary Susan	Reg. No. 38,729	Pollinger, Steven J.	Reg. No. 35,326
Batzli, Brian H.	Reg. No. 32,960	Gates, George H.	Reg. No. 33,500	Reich, John C.	Reg. No. 37,703
Beard, John L.	Reg. No. 27,612	Golla, Charles E.	Reg. No. 26,896	Reiland, Earl D.	Reg. No. 25,767
Beck, Robert C.	Reg. No. 28,184	Gorman, Alan G.	Reg. No. 38,472	Schmidt, Cecil C.	Reg. No. 20,566
Bejin, Thomas E.	Reg. No. 37,089	Gould, John D.	Reg. No. 18,223	Schuman, Mark D.	Reg. No. 31,197
Berman, Charles	Reg. No. 29,249	Gresens, John J.	Reg. No. 33,112	Schumann, Michael D.	Reg. No. 30,422
Bogucki, Raymond A.	Reg. No. 17,426	Haare, Curtis B.	Reg. No. 29,165	Sebald, Gregory A.	Reg. No. 33,280
Bruess, Steven C.	Reg. No. 34,130	Hassing, Thomas A.	Reg. No. 36,159	Sharp, Janice A.	Reg. No. 34,051
Byrne, Linda M.	Reg. No. 32,404	Hillson, Randall A.	Reg. No. 31,838	Smith, Jerome R.	Reg. No. 35,684
Carlson, Alan G.	Reg. No. 25,959	Hollingsworth, Mark A.	Reg. No. 38,491	Sorensen, Andrew D.	Reg. No. 33,606
Carter, Charles G.	Reg. No. 35,093	Kastelic, Joseph M.	Reg. No. 37,160	Stinebruner, Scott A.	Reg. No. 38,323
Caspers, Philip P.	Reg. No. 33,227	Kowalchuk, Alan W.	Reg. No. 31,535	Strawbridge, Douglas A.	Reg. No. 28,376
Clifford, John A.	Reg. No. 30,247	Kowalchuk, Katherine M.	Reg. No. 36,848	Strodthoff, Kristine M.	Reg. No. 34,259
Conrad, Timothy R.	Reg. No. 30,164	Krull, Mark A.	Reg. No. 34,205	Sumner, John P.	Reg. No. 29,114
Crawford, Robert	Reg. No. 32,122	Lacy, Paul A.	Reg. No. P-38,946	Summers, John S.	Reg. No. 24,216
Daignault, Ronald A.	Reg. No. 25,968	Lasky, Michael B.	Reg. No. 29,555	Tellekson, David K.	Reg. No. 32,314
Daley, Dennis R.	Reg. No. 34,994	Lynch, David W.	Reg. No. 36,204	Underhill, Albert L.	Reg. No. 27,403
Daulton, Julie R.	Reg. No. 36,414	Mau, Michael L.	Reg. No. 30,087	Vandenburgh, J. Derek	Reg. No. 32,179
Dempster, Shawn B.	Reg. No. 34,321	McDonald, Daniel W.	Reg. No. 32,044	Vietzke, Lance L.	Reg. No. 36,708
DiPietro, Mark J.	Reg. No. 28,707	McDonald, Wendy M.	Reg. No. 32,427	Welter, Paul A.	Reg. No. 20,890
Edell, Robert T.	Reg. No. 20,187	Mueller, Douglas P.	Reg. No. 30,300	Williams, Douglas J.	Reg. No. 27,054
Farber, Michael B.	Reg. No. 32,612	Nelson, Albin J.	Reg. No. 28,650	Wood, Gregory B.	Reg. No. 28,133
Fauver, Cole M.	Reg. No. 36,797	Plunkett, Theodore	Reg. No. 37,209		

I hereby authorize them to act and rely on instructions from and communicate directly with the person/assignee/attorney/firm/organization/who/which first sends/sent this case to them and by whom/which I hereby declare that I have consented after full disclosure to be represented unless/until I instruct Merchant, Gould to the contrary.

Please direct all correspondence in this case to Merchant, Gould, Smith, Edell, Welter & Schmidt at the address indicated below:

Merchant, Gould, Smith, Edell,
Welter & Schmidt
3100 Norwest Center
90 South Seventh Street
Minneapolis, MN 55402-4131

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

201	Full Name of Inventor	FIRST NAME Nabil	MIDDLE INITIAL	LAST NAME ABDUL MALAK
	Residence & Citizenship	CITY CALUIRE	STATE OR FOREIGN COUNTRY France	CITIZENSHIP French
	Post Office Address	POST OFFICE ADDRESS 27 Rue Frédéric Mistral	CITY 69300 - CALUIRE	STATE/ZIP/COUNTRY France
SIGNATURE OF INVENTOR 201 <i>Nabil ABDUL-MALAK</i>				DATE July 4, 2000
202	Full Name of Inventor	FIRST NAME Valérie	MIDDLE INITIAL	LAST NAME ANDRE
	Residence & Citizenship	CITY AMPUIS	STATE OR FOREIGN COUNTRY France	CITIZENSHIP French
	Post Office Address	POST OFFICE ADDRESS 15 Rue de Montlys Verenay	CITY 69420 - AMPUIS	STATE/ZIP/COUNTRY France
SIGNATURE OF INVENTOR 202 <i>Valérie Anelie</i>				DATE July 4, 2000
203	Full Name of Inventor	FIRST NAME Alain	MIDDLE NAME	LAST NAME HUC
	Residence & Citizenship	CITY STE.FOY LES LYON	STATE OR FOREIGN COUNTRY France	CITIZENSHIP French
	Post Office Address	POST OFFICE ADDRESS 26 Chemin des Santons	CITY 69110 - STE. FOY LES LYON	STATE/ZIP/COUNTRY France
SIGNATURE OF INVENTOR 203 <i>Alain Huc</i>				DATE July 4, 2000

or Additional Inventors:

Indicate here and attach sheet with same information, including date and signature.

S/N unknown

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: ABDUL MALAK et al. Serial No.: unknown
Filed: concurrent herewith Docket No.: 11123.15US01
Title: PROCESSES FOR THE PREPARATION OF NOVEL COLLAGEN-BASED
SUPPORTS FOR TISSUE ENGINEERING, AND BIOMATERIALS
OBTAINED

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL 544511576US

Date of Deposit: Linda McCormick

I hereby certify that this correspondence is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

By:

Name: Linda McCormick

COMMUNICATION REGARDING CHANGE OF CORRESPONDENCE ADDRESS

BOX NEW APP
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In connection with the above-identified application, please direct all correspondence in this case to Merchant & Gould P.C. at the address indicated below:

Merchant & Gould P.C.
P.O. Box 2903
Minneapolis, MN 55402-0903

If a telephone conference would be helpful in resolving any issues concerning this communication, please contact Applicant's primary attorney-of record, John J. Gresens (Reg. No. 33,112), at (612) 371-5265.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Dated: July 14, 2000

By

John J. Gresens

Reg. No. 33,112

JJG:jjw